Inclusion Criteria:

          1. Signed the informed consent form (ICF);

          2. Recurrent or advanced stage Ⅲ B or IV non-small cell lung cancer tested for EGFR
             mutation and ALK, ROS1 fusion gene, and all the driving gene was negative.

          3. At least one measurable lesion (according to RECIST 1.1);

          4. Failure of previous first-line standard chemotherapy:

          5. Patients who agreed to provide previously stored tumor tissue specimens or fresh
             biopsies of tumor lesions

          6. Age 18-75 years old, regardless of gender;

          7. ECOG score 0-1;

          8. Expected survival time ≥ 3 months;

          9. Laboratory test value must show enough organ function

        Exclusion Criteria:

          1. Tumor histology or cytological pathology confirmed the presence of small cell lung
             cancer components, or sarcomatoid lesions;

          2. Those who did not have a driving gene test;

          3. Investigator believed that there was a clear bleeding tendency

          4. Subjects who are currently participating in and receiving treatment in other studies,
             less than 4 weeks

          5. Patients who had previously received second-line or more systemic chemotherapy for
             advanced NSCLC;

          6. Patients who had received hematopoietic stimulating factors, within one week before
             the start of the study.

          7. Uncontrollable or symptomatic hypercalcemia

          8. Within 6 months before receiving the study treatment, they received chest (lung)
             radiotherapy > 30Gy, or received radiotherapy within 4 weeks or radiopharmaceuticals
             within 8 weeks, except for local palliative radiotherapy for bone metastases.

          9. The adverse reactions of previous antineoplastic therapy have not yet recovered to
             CTCAE 5.0 grade ≤ 1 (except alopecia);

         10. Major surgery or radiotherapy has been performed within 4 weeks before joining the
             group or has not yet fully recovered from the previous operation

         11. Known active central nervous system (CNS) metastasis and / or cancerous meningitis;

         12. Spinal cord compression without radical treatment of surgery and / or radiotherapy;

         13. Uncontrolled tumor-related pain;

         14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage ;

         15. Evidence of active pneumonia was found;

         16. Clinically uncontrolled active infections;

         17. Uncontrollable major seizures or superior vena cava syndrome;

         18. Past or present co-existence of other malignant tumors;

         19. Liver diseases known to be of clinical significance;

         20. Those who have previously used any anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2
             antibody or anti-CTLA-4 antibody and Axitinib;

         21. Patients with active tuberculosis (TB);

         22. Patients with any active autoimmune disease or history of autoimmune disease;

         23. Any anti-infective vaccine;

         24. Known (HIV) infection of human immunodeficiency virus;

         25. The researchers believe that it can affect study compliance;

         26. Patients who received systemic immunosuppressive drugs within the first 4 weeks of the
             first day of the first cycle;

         27. History of severe allergy, anaphylaxis or other hypersensitivity to chimeric or
             humanized antibodies or fusion proteins;

         28. Those who are known to be allergic to biological drugs;

         29. Those who are known to be allergic to acitinib;

         30. Patients with a history of arterial or venous thromboembolism;

         31. Known hereditary or acquired bleeding and thrombotic tendencies;

         32. Patients who have previously received allogeneic stem cell or parenchyma organ
             transplantation;

         33. Pregnant or lactating women or women of childbearing age who were positive for serum
             pregnancy test before taking the drug for the first time